BMFZ-Meeting 2019

BMFZ-Meeting- 24.09.2019, Gene Therapy, Vorwort  AB (DW)

Currently, more than 370 registered gene therapy trials are in progress. The field has been exploded since the first authorised gene transfer study took place in 1989. In this landmark study, tumor-infiltrating lymphocytes were modified and re-infused with the intention to increase their tumour-homing capacity. Since then, gene-therapy based treatment of several primary immunodeficiencies, haemophilia B, Leber congenital amaurosis, and X-linked adrenoleukodystrophy (X-ALD) paved the way for many other diseases. More recently, cancer immunotherapy using CAR T cells, gene correction of hemoglobinopathies and the new methodological possibilities of genome editing by the CRISPR/Cas system have received widespread attention. Even if at a preclinical stage, efficient strategies that use non-homologous end-joining to correct pathogenic splice-mutations hold great promise for the future. At least five EMA and/or FDA-approved gene-therapy products are on the market, and gene therapy clinicial trials have now been conducted in all five continents. All in all, gene therapy has become an exiciting field for basic reesearchers, clinicial scientists and pharma industry.

The Centre of Biological and Medical Research of the Heinrich-Heine-University Dusseldorf kindly  invites not only colleagues, postdocs and PhD/MD students but also interested laypersons to discuss the latest developments in the field. We thank all our renowned speakers who accepted our invitation to come to Dusseldorf to join our annual meeting 2019!

Arndt Borkhardt                                                                             Dagmar Wieczorek


undefinedZur Anmeldung senden Sie bitte eine Email an BMFZ[at]

Verantwortlich für den Inhalt: E-Mail sendenRedaktionsteam BMFZ